plb1001
Small moleculeexperimental
Clinical trial activity
16 trials · 12 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
12
Phase 3
3
Phase 4
0
Earliest trial started Apr 1, 2016 (NCT02896231)
Timeline
Indications
Mechanism of action
- Hepatocyte growth factor receptorINHIBITOR
MET inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cn1cc2cc(C(F)(F)c3nnc4ccc(-c5cnn(C6CC6)c5)nn34)c(F)cc2n1- Mol. weight
- 424.39 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650443 ↗
Also known as
- plb1001
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07153887 | Phase 2 | Sep 30, 2025 | Zhejiang University |
| NCT07156604 | Phase 2 | Sep 30, 2025 | Fudan University |
| NCT06970782 | Phase 3 | May 15, 2025 | Avistone Biotechnology Co., Ltd. |
| NCT07087223 | Phase 1/Phase 2 (Phase 2) | Apr 8, 2025 | Peking University |
| NCT06780592 | Phase 2 | Jan 13, 2025 | Capital Medical University, Fudan University |
| NCT06644313 | Phase 2 | Nov 1, 2024 | Huazhong University of Science and Technology |
| NCT06739395 | Phase 2 | Nov 1, 2024 | Tianjin Medical University |
| NCT06827145 | Phase 2 | Oct 14, 2024 | Avistone Biotechnology Co., Ltd., Chinese Academy of Medical Sciences, National Cancer Center, China |
| NCT06574347 | Phase 2 | Aug 7, 2024 | Avistone Biotechnology Co., Ltd., Shantou University |
| NCT05989542 | Phase 3 | Jun 29, 2023 | Beijing Pearl Biotechnology Limited Liability Company, Shantou University |
| NCT06343064 | Phase 1/Phase 2 (Phase 2) | Jun 13, 2023 | Avistone Biotechnology Co., Ltd. |
| NCT05367388 | Phase 1 | May 20, 2022 | Apollomics, Inc. |
| NCT04258033 | Phase 2 | Jan 17, 2020 | Beijing Pearl Biotechnology Limited Liability Company, Shantou University |
| NCT06105619 | Phase 2/Phase 3 (Phase 3) | Oct 8, 2018 | Beijing Pearl Biotechnology Limited Liability Company, Capital Medical University |
| NCT02978261 | Phase 1 | Sep 1, 2016 | Beijing Pearl Biotechnology Limited Liability Company, Capital Medical University |
| NCT02896231 | Phase 1 | Apr 1, 2016 | Beijing Pearl Biotechnology Limited Liability Company, Shantou University |
Showing 16 of 16 trials
Page 1 / 1
Organizations
Research & Development (12)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Beijing Pearl Biotechnology Limited Liability Company | Government | 5 | 5 | 3 | 2016 |
| Avistone Biotechnology Co., Ltd. | For profit | 4 | 3 | 2 | 2023 |
| Shantou University | Academic/Hospital | 4 | 0 | 3 | 2016 |
| Capital Medical University | Academic/Hospital | 3 | 0 | 3 | 2016 |
| Fudan University | Academic/Hospital | 2 | 2 | 1 | 2025 |
| Apollomics, Inc. | For profit | 1 | 1 | 1 | 2022 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 1 | 1 | 2024 |
| National Cancer Center, China | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Peking University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Tianjin Medical University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Zhejiang University | Academic/Hospital | 1 | 1 | 1 | 2025 |
12 organizations
Page 1 / 1